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Background: Recently, cyclooxygenase-2 (COX-2) has become an important new target in the field of tumor
metastasis. However, the relationship between COX-2 gene expression and the behavior of osteosarcoma metastasis
is largely unknown. The study is to investigate how antisense oligonucleotides (ODNs) of COX-2 inhibit the invasion
of human osteosarcoma cell line OS-732 and their mechanism of regulation.
Methods: A COX-2 antisense oligonucleotide was designed, synthesized, and transfected into OS-732 human
osteosarcoma cells. RT-PCR and western blotting were performed to determine the transfection efficiency. A
modified Boyden-transwell assay was used to measure the inhibition rate of tumor cell invasion. In OS-732 cells
transfected with COX-2 antisense ODNs, RT-PCR was used to examine the mRNA expression of urokinase-type
plasminogen activator (uPA) and that of its receptor, uPAR.
Results: Both the mRNA and protein expression levels of COX-2 were significantly reduced when cells were
transfected with COX-2 antisense ODNs, which significantly reduced the invasive ability of OS-732 cells in a
dose-dependent manner. The expression levels of uPA and uPAR were also significantly reduced (p < 0.01).
Conclusion: COX-2 antisense ODNs significantly inhibited the invasion of OS-732 cells, primarily by decreasing the
mRNA expression of uPA and uPAR.
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Osteosarcoma is the most common form of malignant
bone tumor, and it occurs most often in teenagers. It
causes significant harm with poor prognosis, and it is
very difficult to cure.
During the past two decades, the emergence of neoadju-
vant chemotherapy of osteosarcoma has greatly improved
the survival rate of osteosarcoma patients, but nearly half
of these patients are not sensitive to chemotherapeutic
drugs and die due to lung metastasis within 2 to 3 years.
The majority of patients (80%) have small tumor foci
transferred into their systemic blood before treatment;
the importance of improving long-term survival in pa-
tients by controlling lung metastases through effective
drug and gene regulation has been increasingly recog-
nized [1,2]. The invasive ability of tumor cells is one of* Correspondence: doctorwx@hotmail.com
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reproduction in any medium, provided the orthe important factors in their capacity to metastasize to
distant locations in the body [3].
Recently, cyclooxygenase-2 (COX-2) has become a im-
portant new target in the tumor metastasis field [4]. Previ-
ous studies have found that either COX-2 inhibitors or
knockout of the COX-2 gene can inhibit tumor develop-
ment and invasion [5]. However, the relationship between
COX-2 gene expression and the behavior of osteosarcoma
metastasis is largely unknown. This project is attempted
to investigate the role and mechanism of COX-2 antisense
oligonucleotides in regulating the invasion of OS-732
human osteosarcoma cell line.Materials and methods
Materials
OS-732 cells were purchased from Beijing Jishuitan Ortho-
paedic Laboratory. RPMI-1640 medium (Gibco Company),
lipofectamine2000 transfection reagent (Invitrogen), Trizol
(Sangon, Shanghai), one-step RT-PCR kit (TaKaRa, Dalian),
Matrigel in vitro membrane matrix gel (Peking University),. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 The expression of COX-2 mRNA (12 hours after transfection) a. COX-2 mRNA (488 bp) (1. The control group, 2. Lipofectin
group, 3. C1 group: 100 nmol/L, 4. C2 group: 200 nmol/L, 5. C3 group: 400 nmol/L, 6. C4 group: 800 nmol/L); b. GAPDH as an internal
control (330 bp).
Table 1 The influence of COX-2 antisense oligonucleotides








Wu et al. Cancer Cell International 2014, 14:27 Page 2 of 6
http://www.cancerci.com/content/14/1/27and Transwell cell culture membrane (Coring Costar)
were used. Specific primers for COX-2, uPA and uPAR
were synthesized by Sangon Shanghai, and COX-2 anti-
body was purchased from Santa Cruz. Our study was
approved by an ethics committee of the Shanghai tenth
People’s Hospital, China.
Methods
Synthesis of COX-2 antisense ODNs
The sequence of the COX-2 antisense ODN was 5′
GCGGCGACGCTACGAGCGGGCGCGGGACGACG
ACACG 3′. It was synthesized by Sangon Shanghai.
The three phosphate bonds of both the 5′and 3′ ends
were modified by sulfide. The 5′end was labeled with
fluorescein isothiocyanate (FITC).
Transfection of COX-2 AS-ODN
Lipofectin was used for the transfection. The final
concentrations of COX-2 AS-ODNs at 100 nmol/L (C1
group), 200 nmol/L (C2 group), 400 nmol/L (C3 group),
or 800 nmol/L (C4 group) were used for the transfec-
tion experiments. The transfection procedure was as
follows: ① OS-732 cells were seeded at 1 × 105 cells/well
in a 6-well plate and cultured overnight. ② Measures of
2 -25 μL of Lipofectin liposomes were diluted to 100 μL
by serum-free antibiotic-free RPMI-1640 medium in
sterile Eppendorf tubes. The AS-ODNs were added to
another Eppendorf tube, diluted to 100 μL by RPMI-
1640 medium with the same conditions, and incubated
at room temperature for 10 min. ③ After 10 min, the
above two solutions were mixed gently with a pipette
until uniform and incubated at room temperature for 15-
45 min to form the liposome-oligonucleotide complex.Figure 2 The protein expression of COX-2 by western blotting
(0.The control group, 1. Lipofectin group, 2. COX-2 AS-ODN:
100 nmol/L, 3. COX-2 AS-ODN: 400 nmol/L).Then 0.8 mL of antibiotic-free serum-free RPMI-1640
medium was added, bringing the total transfection vol-
ume to 1 mL. ④ Cells in the 6-well plate were washed
three times with serum-free medium at 4, followed by a
final wash with antibiotic-free medium. The liposome-
oligonucleotide complex was then added dropwise into
cells. The plate was gently rotated to ensure uniform
distribution and then returned to the incubator in 5%
CO2 at 37°C. ⑤ After 6 h, the liposome-oligonucleotide-
containing medium was removed and 2 ml RPMI-1640
medium with 10% fresh fetal calf serum was added. The
cells were cultured for additional 24-48 h.
Detection of the mRNA expression level in COX-2, uPA
and uPAR
The total RNA was extracted with Trizol, and one-step
RT-PCR was used to detect COX-2, uPA and uPAR
mRNA expression. The 50 μL reaction system contains
5 mmol/L MgCl2, 1 mmol/L dNTPs, 0.1 U/μL AMV-Taq,
1 μg of upstream primer, 1 μg of downstream primer, 1 μg
of total RNA. Reverse transcription was performed at
50°C for 30 min, and denaturation was performed at
94°C for 2 min. This was followed by PCR for 30 cycles
with the following program: 94°C for 30 s, 56°C for 30 s
and 72°C for 1 min. COX-2 upstream primer: 5′-TCAA
GTCCCTGAGCATCTAC-3′, COX-2 downstream pri-
mer: 5′-CATTCCTACCACCAGCAAC C-3′; COX-2
product size is 488 bp. uPA upstream primer: 5′-AGABlank 34.42 ± 4.78 0 -
Control 31.65 ± 5.81 9.43 ± 2.72 >0.05
50 26.56 ± 3.45 22.85 ± 7.12 <0.05
100 23.26 ± 4.66 32.42 ± 10.26 <0.05
200 17.54 ± 3.36 53.47 ± 9.35 <0.05
400 12.75 ± 3.22 64.67 ± 8.66 <0.01
800 11.86 ± 2.85 67.22 ± 7.52 <0.01
Note: Levene statistics was used to confirm the homogeneity of variance
between the experimental groups. One-way ANOVA with Bonferroni correction
of p-values was used for the movement inhibition ratio.
Figure 3 The influence of COX-2 antisense oligonucleotides on osteosarcoma cell invasion.
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mer: 5′-ATC AGC TTC ACA ACA GTC AT-3′; uPA
product size is 474 bp. uPAR upstream primer: 5′-AGG
TGA AGA AGG GCG TCCAA-3′, uPAR downstream
primer: 5′-TTC AGG TTT AGGTCC AGA GG-3′; uPAR
product size is 553 bp. GAPDH upstream primer: 5′-CTC
CCC CTA CTA TCT CTT TC-3′, GAPDH downstream
primer: 5′-CAT CTC TCC ATC CCA CTT AAC-3′;
GAPDH product size is 330 bp.
Western blotting to detect COX-2 protein expression
Cells were lysed by the M-PERTM protein lysate at 4°C
and centrifuged at 1500 × g for 15 min. The supernatant
was transferred to a new EP tube, where the proteins
were concentrated, subjected to SDS-PAGE, and trans-
ferred to a nitrocellulose membrane, which was blocked
overnight. COX-2 antibodies were used to incubate the
membrane overnight, and then the appropriate second-
ary antibody was added and incubated for 1 h at 37°CFigure 4 The number of trans-membrane cells (×200). a. The control g
COX-2 AS-ODN transfection group (800 nmol/L).after the membrane was thoroughly washed with TBS.
The signal was visualized using an ECL detection system.
Invasion assay: a modified Boyden-transwell assay
was used
1) An 8 μm pore size Transwell microporous membrane
was covered with 1 mg/mL Matrigel. Then 500 μL of
tumor chemokine was added into the lower chamber,
and 100 μL of cell suspension (containing 1 × 105 cells)
was added into the upper chamber. The non-transfected
control group, the empty vector-transfected liposome
control group and the experimental group (divided into
5 subgroups in which the concentrations of COX-2 AS-
ODNs were 50, 100, 200, 400 and 800 nmol/L, respect-
ively, in transfected cells) were incubated for 4 h. Then the
membranes were removed, fixed by methanol for 5 min
and Giemsa stained. Cells on the back of the membrane
were counted with a microscope at 200 times magnifi-
cation. The cells in the middle and four corners wereroup, b. The COX-2 AS-ODN transfection group (100 nmol/L), c. The
Table 2 Density ratios from the target gene and internal
control of samples in each group xsÞð
Group uPA uPAR
0 nmol/L 0.89 ± 0.08 0.76 ± 0.05
200 nmol/L 0.75 ± 0.07 0.58 ± 0.06
400 nmol/L 0.62 ± 0.07 0.36 ± 0.05
800 nmol/L 0.35 ± 0.05 0.24 ± 0.02
P <0.01 <0.01
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rate% = (number of invasive cells in the control group -
number of invasive cells in the experimental group)/
number of invasive cells in the control group × 100.
Results
The influence of COX-2 antisense ODN transfection on
the expression of COX-2 in OS-732 cells. As shown by
RT-PCR, the COX-2 mRNA expression levels were grad-
ually reduced in a dose-dependent manner; however, the
relationship was not linear. When transfected at a certain
concentration (400 nmol/L), the COX-2 mRNA expres-
sion declined slowly (Figure 1). In a time-effect relation-
ship, COX-2 antisense ODNs had the strongest effect
12 hours after transfection and then gradually lost po-
tency. Transfection itself did not affect the expression of
COX-2, as shown by western blot; however, COX-2 anti-
sense ODNs significantly inhibited the expression of
COX-2, and the higher dose of COX-2 antisense ODNs
resulted in a greater decrease of COX-2 protein expression
(Figure 2).
Transwell invasion experiments showed that the num-
ber of trans-membrane cells of the negative control group
was 34.42 ± 4.78 at 200 × magnification. That of the empty
vector-transfected group was 30.65 ± 5.81, which was not
statistically significant different (p > 0.05) from the control
group. However, in the COX-2 antisense oligonucleotide
transfection group, the invasion capacity of those cells was
significantly decreased: the number of transmembrane
cells for each subgroup was significantly different when
compared with the control group, and the 400 nmol/L
and 800 nmol/L groups were the most statistically signifi-
cant (p < 0.01) (Table 1, Figure 3, 4).
The influence of COX-2 antisense oligonucleotides on
mRNA expression in OS-732 cells.Figure 5 RT-PCR amplification: a. uPA, b. uPAR, group 0, 1, 2 and 3 (CThe specific PCR fragments of uPA, uPAR and GAPDH
were amplified by RT-PCR in both the experimental group
and the control group.
The optical density ratios of the uPA mRNA amplifi-
cation products in cells transfected with 0, 200, 400, or
800 nmol/L COX-2 antisense ODNs were 0.89 ± 0.08,
0.75 ± 0.07, 0.62 ± 0.07 and 0.35 ± 0.05, respectively. There
were significant differences between subgroups (p < 0.01)
(Table 2).
The optical density ratios of the uPAR mRNA amplifi-
cation product in cells transfected with 0, 200, 400,
800 nmol/L COX-2 antisense ODNs were 0.76 ± 0.05,
0.58 ± 0.06, 0.36 ± 0.05 and 0.24 ± 0.02, respectively. There
were significant differences between subgroups (p <0.01)
(Table 2).
As can be seen, the expression of COX-2 antisense oli-
gonucleotides decreased the expression of both uPA and
uPAR mRNA in a dose-dependent manner (Figure 5).
Discussion
Cyclooxygenase-2 (COX-2) has been a hot new target of
tumor metastasis in recent studies. COX-2 is a rate-
limiting enzyme in the synthesis of prostaglandin E2,
which is not normally expressed in most tissues. How-
ever, COX-2 can be induced by cancer-promoting
agents, cytokines, growth factors and hypoxia-inducible
factors [6].
In recent years, a remarkable discovery for oncology is
that the overexpression of COX-2 is closely related with
tumor development. COX-2 is considered to be a new and
important target for the treatment of a variety of tumors
because COX-2 inhibitors or knockout of the COX-2 gene
can inhibit both tumor development and metastasis [7].
Numerous studies [8-11] showed that COX-2 promotes
tumor cell invasion and metastasis through various means,
including the regulation of downstream genes, in gastro-
intestinal cancer, lung cancer, breast cancer and other
cancers.
Recently, it has been reported that COX-2 is overex-
pressed in osteosarcoma and is significantly expressed in
metastatic lesions [12]. Some selective COX-2 inhibitors
inhibited cell growth and induced apoptosis of osteosar-
coma cells in vitro. However, the exact role of COX-2 in
osteosarcoma invasion is not fully understood. Whether
knockout or knockdown of COX-2 expression couldOX-2 AS-ODN at 0, 200, 400 or 800 nmol/L).
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well studied.
Malignant tumor invasiveness is an important part of
cancer transformation. In the process of tumor invasion,
the migration of tumor cells and their distribution to
other tissues and organs could be restricted by local
organizations, which requires the degradation of the
extracellular matrix.
The degradation of the extracellular matrix requires
the involvement of a variety of extracellular proteolytic
enzymes, with which the urokinase-type plasminogen
activator (uPA) and its receptor (uPAR) play important
roles [13]. uPA interacts with uPAR at the tumor cell
surface, with uPA concentrated on the cell surface. uPA
is the initiation factor, activating the conversion of plas-
minogen into plasmin. Plasmin can directly degrade
matrix components or further activate metalloprotein-
ases to degrade the matrix, thereby promoting tumor
cell invasion and metastasis [14-16]. The binding of uPA
to uPAR also mediates the signal transduction to promote
cathepsin B and 92 kDa collagenase expression; to cause
non-receptor protein tyrosine kinase phosphorylation of
keratin and src family and the activation of the Jak/Stat
pathway; and to regulate tumor cell proliferation, differen-
tiation, movement and angiogenesis [17-20].
At the same time, uPAR can be combined with matrix
vitronectin and interact with integrins to mediate cell
adhesion and movement [21]. Recently [22], uPAR was
reported to be a chemokine, which is conducive for
tumor cell invasion.It has been proven that the expression
of uPA and uPAR was significantly increased in many
high-metastatic tumor cells, such as osteosarcoma cells.
Higher the expression of uPA and uPAR is associated with
worse prognosis and a shorter survival time [23].
In this study, the invasive ability of osteosarcoma cells
was detected with the modified Boyden-transwell chamber
method. When the concentration of transfected COX-2
antisense oligonucleotides reached 50 nmol/L, the inhib-
ition of tumor invasion was statistically significant; at a
concentration of 200 nmol/L, the inhibition rate of tumor
cell invasion is 50%, and at a concentration of 800 nmol/L,
the inhibition rate reached a plateau.
Molecular biology experiments show that COX-2
antisense oligonucleotides significantly reduced uPA and
uPAR mRNA expression in OS-732 cells, and that the
effect increased in a dose-dependent manner. Blocking the
initial part of invasion could be one of most important
mechanisms of COX-2 antisense oligonucleotides in the
regulation of the invasive ability of osteosarcoma cells.
The significance of our research is that it has increased
our understanding of the relationship between COX-2
gene expression and osteosarcoma cell invasion, which
can not only provide research ideas for the inhibition of
the metastasis of osteosarcoma cells but also provide atheoretical basis for fighting osteosarcoma metastasis with
selective COX-2 inhibitors.
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